Alteration of gut microbiota induced by DPP-4i treatment improves glucose homeostasis

EBioMedicine

Volumn 44, Issue , 2019, Pages 665-674

  Liao, Xiaoyu ^a   Song, Lingyu ^a,e   Zeng, Benhua ^a   Liu, Bingyao ^a   Qiu, Yuyang ^a   Qu, Hua ^a   Zheng, Yi ^a   Long, Min ^a   Zhou, Houdi ^a   Wang, Yuan ^a   Du, Yingxuan ^a   Xu, Jing ^a   Shen, Rufei ^a   Tong, Qiang ^a   Cai, Leiqin ^a   Li, Xing ^a   Guo, Shaodong ^b   Yang, Gangyi ^c   Zhu, Zhiming ^d   Pu, Xiaoyun ^a   Wei, Hong ^a   Zheng, Hongting ^a   more..

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b TEXAS A AND M UNIVERSITY   (United States)

^c CHONGQING MEDICAL UNIVERSITY   (China)

^d THIRD MILITARY MEDICAL UNIVERSITY   (China)

^e GUIZHOU MEDICAL UNIVERSITY   (China)

Author keywords

DPP 4i; GF mice; Glucose tolerance; Gut microbiota

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BACITRACIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DNA 16S; GENOMIC DNA; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; LIRAGLUTIDE; SAXAGLIPTIN; SITAGLIPTIN; SUCCINIC ACID; VANCOMYCIN; ANTIINFECTIVE AGENT; INSULIN;

ADULT; AGED; AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTEROIDACEAE; BACTEROIDETES; BODY WEIGHT GAIN; CALORIC INTAKE; CARBOHYDRATE METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DESULFOVIBRIONACEAE; DNA EXTRACTION; FECAL MICROBIOTA TRANSPLANTATION; FECES ANALYSIS; FIRMICUTES; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INTESTINE FLORA; MALE; MASS FRAGMENTOGRAPHY; METABOLOMICS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEIC ACID METABOLISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; RUMINOCOCCACEAE; STREPTOCOCCACEAE; ANIMAL; DISEASE MODEL; DRUG EFFECT; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; LIPID DIET; METABOLISM; METAGENOME; METAGENOMICS; PROCEDURES;

ANIMALS; ANTI-BACTERIAL AGENTS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE MODELS, ANIMAL; GASTROINTESTINAL MICROBIOME; GLUCOSE; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HUMANS; INSULIN; MALE; METAGENOME; METAGENOMICS; MICE;

EID: 85063282512     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2019.03.057     Document Type: Article

References (69)

1. Eckburg, P.B., Bik, E.M., Bernstein, C.N., Purdom, E., Dethlefsen, L., Sargent, M., et al. Diversity of the human intestinal microbial flora. Science 308:5728 (2005), 1635–1638.
2. Gill, S.R., Pop, M., Deboy, R.T., Eckburg, P.B., Turnbaugh, P.J., Samuel, B.S., et al. Metagenomic analysis of the human distal gut microbiome. Science (New York, NY) 312:5778 (2006), 1355–1359.
3. Bruce-Keller, A.J., Salbaum, J.M., Berthoud, H.R., Harnessing gut microbes for mental health: getting from here to there. Biol Psychiatry 83:3 (2018), 214–223.
4. Scher, J.U., Abramson, S.B., The microbiome and rheumatoid arthritis. Nat Rev Rheumatol 7:10 (2011), 569–578.
5. Chu, H., Khosravi, A., Kusumawardhani, I.P., Kwon, A.H., Vasconcelos, A.C., Cunha, L.D., et al. Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease. Science (New York, NY) 352:6289 (2016), 1116–1120.
6. Zheng, P., Zeng, B., Zhou, C., Liu, M., Fang, Z., Xu, X., et al. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host's metabolism. Mol Psychiatry 21:6 (2016), 786–796.
7. Lynch, S.V., Pedersen, O., The human intestinal microbiome in health and disease. N Engl J Med 375:24 (2016), 2369–2379.
8. Shapiro, H., Suez, J., Elinav, E., Personalized microbiome-based approaches to metabolic syndrome management and prevention. J Diabetes 9:3 (2017), 226–236.
9. Ley, R.E., Turnbaugh, P.J., Klein, S., Gordon, J.I., Microbial ecology: human gut microbes associated with obesity. Nature 444:7122 (2006), 1022–1023.
10. Karlsson, F.H., Tremaroli, V., Nookaew, I., Bergstrom, G., Behre, C.J., Fagerberg, B., et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 498:7452 (2013), 99–103.
11. Backhed, F., Ding, H., Wang, T., Hooper, L.V., Koh, G.Y., Nagy, A., et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 101:44 (2004), 15718–15723.
12. Ley, R.E., Backhed, F., Turnbaugh, P., Lozupone, C.A., Knight, R.D., Gordon, J.I., Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 102:31 (2005), 11070–11075.
13. Everard, A., Lazarevic, V., Derrien, M., Girard, M., Muccioli, G.G., Neyrinck, A.M., et al. Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes 60:11 (2011), 2775–2786.
14. Cani, P.D., Neyrinck, A.M., Fava, F., Knauf, C., Burcelin, R.G., Tuohy, K.M., et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 50:11 (2007), 2374–2383.
15. Everard, A., Matamoros, S., Geurts, L., Delzenne, N.M., Cani, P.D., Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice. mBio, 5(3), 2014 [e01011-14].
16. Furet, J.P., Kong, L.C., Tap, J., Poitou, C., Basdevant, A., Bouillot, J.L., et al. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 59:12 (2010), 3049–3057.
17. Shin, N.R., Lee, J.C., Lee, H.Y., Kim, M.S., Whon, T.W., Lee, M.S., et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 63:5 (2014), 727–735.
18. Wu, H., Esteve, E., Tremaroli, V., Khan, M.T., Caesar, R., Manneras-Holm, L., et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med 23:7 (2017), 850–858.
19. Bauer, P.V., Duca, F.A., Waise, T.M.Z., Rasmussen, B.A., Abraham, M.A., Dranse, H.J., et al. Metformin alters upper small intestinal microbiota that impact a glucose-SGLT1-sensing glucoregulatory pathway. Cell Metab 27:1 (2018), 101–117 [e5].
20. Zhao, L., Chen, Y., Xia, F., Abudukerimu, B., Zhang, W., Guo, Y., et al. A glucagon-like peptide-1 receptor agonist lowers weight by modulating the structure of gut microbiota. Front Endocrinol (Lausanne), 9, 2018, 233.
21. Moreira, G.V., Azevedo, F.F., Ribeiro, L.M., Santos, A., Guadagnini, D., Gama, P., et al. Liraglutide modulates gut microbiota and reduces NAFLD in obese mice. J Nutr Biochem 62 (2018), 143–154.
22. Yan, X., Feng, B., Li, P., Tang, Z., Wang, L., Microflora disturbance during progression of glucose intolerance and effect of sitagliptin: an animal study. J Diabetes Res, 2016, 2016, 2093171.
23. Olivares, M., Neyrinck, A.M., Potgens, S.A., Beaumont, M., Salazar, N., Cani, P.D., et al. The DPP-4 inhibitor vildagliptin impacts the gut microbiota and prevents disruption of intestinal homeostasis induced by a Western diet in mice. Diabetologia 61:8 (2018), 1838–1848.
24. Su, B., Liu, H., Li, J., Sunli, Y., Liu, B., Liu, D., et al. Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus. J Diabetes 7:5 (2015), 729–739.
25. Hirsh, A.J., Yao, S.Y., Young, J.D., Cheeseman, C.I., Inhibition of glucose absorption in the rat jejunum: a novel action of alpha-D-glucosidase inhibitors. Gastroenterology 113:1 (1997), 205–211.
26. Holst, J.J., Deacon, C.F., Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 47:11 (1998), 1663–1670.
27. Mentzel, S., Dijkman, H.B., Van Son, J.P., Koene, R.A., Assmann, K.J., Organ distribution of aminopeptidase A and dipeptidyl peptidase IV in normal mice. J Histochem Cytochem 44:5 (1996), 445–461.
28. Hwang, I., Park, Y.J., Kim, Y.R., Kim, Y.N., Ka, S., Lee, H.Y., et al. Alteration of gut microbiota by vancomycin and bacitracin improves insulin resistance via glucagon-like peptide 1 in diet-induced obesity. FASEB J 29:6 (2015), 2397–2411.
29. Perry, R.J., Peng, L., Barry, N.A., Cline, G.W., Zhang, D., Cardone, R.L., et al. Acetate mediates a microbiome-brain-beta-cell axis to promote metabolic syndrome. Nature 534:7606 (2016), 213–217.
30. De Vadder, F., Kovatcheva-Datchary, P., Zitoun, C., Duchampt, A., Backhed, F., Mithieux, G., Microbiota-produced succinate improves glucose homeostasis via intestinal gluconeogenesis. Cell Metab 24:1 (2016), 151–157.
31. Alberti, K.G., Zimmet, P.Z., Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:7 (1998), 539–553.
32. Carrascosa, J.M., Molero, J.C., Fermin, Y., Martinez, C., Andres, A., Satrustegui, J., Effects of chronic treatment with acarbose on glucose and lipid metabolism in obese diabetic Wistar rats. Diabetes Obes Metab 3:4 (2001), 240–248.
33. Kim, S.J., Nian, C., Doudet, D.J., McIntosh, C.H., Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice. Diabetes 57:5 (2008), 1331–1339.
34. Birnbaum, Y., Bajaj, M., Qian, J., Ye, Y., Dipeptidyl peptidase-4 inhibition by Saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome. BMJ Open Diabetes Res Care, 4(1), 2016, e000227.
35. Cai, D., Yuan, M., Frantz, D.F., Melendez, P.A., Hansen, L., Lee, J., et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11:2 (2005), 183–190.
36. Turnbaugh, P.J., Ley, R.E., Mahowald, M.A., Magrini, V., Mardis, E.R., Gordon, J.I., An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444:7122 (2006), 1027–1031.
37. Wang, H., Zhou, J., Liu, Q.Z., Wang, L.L., Shang, J., Simvastatin and Bezafibrate ameliorate emotional disorder induced by high fat diet in C57BL/6 mice. Sci Rep, 7(1), 2017, 2335.
38. Wang, L., Li, P., Tang, Z., Yan, X., Feng, B., Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment. Sci Rep, 6, 2016, 33251.
39. Kim, K.A., Gu, W., Lee, I.A., Joh, E.H., Kim, D.H., High fat diet-induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathway. PLoS One, 7(10), 2012, e47713.
40. Xiao, S., Fei, N., Pang, X., Shen, J., Wang, L., Zhang, B., et al. A gut microbiota-targeted dietary intervention for amelioration of chronic inflammation underlying metabolic syndrome. FEMS Microbiol Ecol 87:2 (2014), 357–367.
41. Zeng, H., Ishaq, S.L., Zhao, F.Q., Wright, A.G., Colonic inflammation accompanies an increase of beta-catenin signaling and Lachnospiraceae/Streptococcaceae bacteria in the hind gut of high-fat diet-fed mice. J Nutr Biochem 35 (2016), 30–36.
42. Sung, M.M., Kim, T.T., Denou, E., Soltys, C.M., Hamza, S.M., Byrne, N.J., et al. Improved glucose homeostasis in obese mice treated with resveratrol is associated with alterations in the gut microbiome. Diabetes 66:2 (2017), 418–425.
43. Evans, C.C., LePard, K.J., Kwak, J.W., Stancukas, M.C., Laskowski, S., Dougherty, J., et al. Exercise prevents weight gain and alters the gut microbiota in a mouse model of high fat diet-induced obesity. PLoS One, 9(3), 2014, e92193.
44. Anhe, F.F., Roy, D., Pilon, G., Dudonne, S., Matamoros, S., Varin, T.V., et al. A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice. Gut 64:6 (2015), 872–883.
45. Zheng, X., Huang, F., Zhao, A., Lei, S., Zhang, Y., Xie, G., et al. Bile acid is a significant host factor shaping the gut microbiome of diet-induced obese mice. BMC Biol, 15(1), 2017, 120.
46. Koh, A., De Vadder, F., Kovatcheva-Datchary, P., Backhed, F., From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell 165:6 (2016), 1332–1345.
47. Handelsman, Y., Bloomgarden, Z.T., Grunberger, G., Umpierrez, G., Zimmerman, R.S., Bailey, T.S., et al. American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract 21:Suppl. 1 (2015), 1–87.
48. Drucker, D.J., Nauck, M.A., The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:9548 (2006), 1696–1705.
49. Bae, E.J., DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control. Arch Pharm Res 39:8 (2016), 1114–1128.
50. Wesley, U.V., Hatcher, J.F., Ayvaci, E.R., Klemp, A., Dempsey, R.J., Regulation of dipeptidyl peptidase IV in the post-stroke rat brain and in vitro ischemia: implications for chemokine-mediated neural progenitor cell migration and angiogenesis. Mol Neurobiol 54:7 (2017), 4973–4985.
51. Maes, M., Bonaccorso, S., Marino, V., Puzella, A., Pasquini, M., Biondi, M., et al. Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation. Mol Psychiatry 6:4 (2001), 475–480.
52. dos Santos, L., Salles, T.A., Arruda-Junior, D.F., Campos, L.C., Pereira, A.C., Barreto, A.L., et al. Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure. Circ Heart Fail 6:5 (2013), 1029–1038.
53. Shah, Z., Kampfrath, T., Deiuliis, J.A., Zhong, J., Pineda, C., Ying, Z., et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 124:21 (2011), 2338–2349.
54. Long, M., Cai, L., Li, W., Zhang, L., Guo, S., Zhang, R., et al. DPP-4 inhibitors improve diabetic wound healing via direct and indirect promotion of epithelial-mesenchymal transition and reduction of scarring. Diabetes 67:3 (2018), 518–531.
55. Wang, H., Liu, X., Long, M., Huang, Y., Zhang, L., Zhang, R., et al. NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. Sci Transl Med, 8(334), 2016, 334ra51.
56. Turnbaugh, P.J., Ridaura, V.K., Faith, J.J., Rey, F.E., Knight, R., Gordon, J.I., The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med, 1(6), 2009, 6ra14.
57. Hildebrandt, M.A., Hoffmann, C., Sherrill-Mix, S.A., Keilbaugh, S.A., Hamady, M., Chen, Y.Y., et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology, 137(5), 2009 [1716–24.e1-2].
58. Topping, D.L., Clifton, P.M., Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev 81:3 (2001), 1031–1064.
59. Muegge, B.D., Kuczynski, J., Knights, D., Clemente, J.C., Gonzalez, A., Fontana, L., et al. Diet drives convergence in gut microbiome functions across mammalian phylogeny and within humans. Science (New York, NY) 332:6032 (2011), 970–974.
60. De Vadder, F., Kovatcheva-Datchary, P., Goncalves, D., Vinera, J., Zitoun, C., Duchampt, A., et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 156:1–2 (2014), 84–96.
61. Soty, M., Gautier-Stein, A., Rajas, F., Mithieux, G., Gut-brain glucose signaling in energy homeostasis. Cell Metab 25:6 (2017), 1231–1242.
62. Reichardt, N., Duncan, S.H., Young, P., Belenguer, A., McWilliam Leitch, C., Scott, K.P., et al. Phylogenetic distribution of three pathways for propionate production within the human gut microbiota. ISME J 8:6 (2014), 1323–1335.
63. Everard, A., Lazarevic, V., Gaia, N., Johansson, M., Stahlman, M., Backhed, F., et al. Microbiome of prebiotic-treated mice reveals novel targets involved in host response during obesity. ISME J 8:10 (2014), 2116–2130.
64. Fischbach, M.A., Sonnenburg, J.L., Eating for two: how metabolism establishes interspecies interactions in the gut. Cell Host Microbe 10:4 (2011), 336–347.
65. Scheifinger, C.C., Wolin, M.J., Propionate formation from cellulose and soluble sugars by combined cultures of Bacteroides succinogenes and Selenomonas ruminantium. Appl Microbiol 26:5 (1973), 789–795.
66. Grasset, E., Puel, A., Charpentier, J., Collet, X., Christensen, J.E., Terce, F., et al. A specific gut microbiota dysbiosis of type 2 diabetic mice induces GLP-1 resistance through an enteric NO-dependent and gut-brain axis mechanism. Cell Metab 25:5 (2017), 1075–1090 [e5].
67. Org, E., Blum, Y., Kasela, S., Mehrabian, M., Kuusisto, J., Kangas, A.J., et al. Relationships between gut microbiota, plasma metabolites, and metabolic syndrome traits in the METSIM cohort. Genome Biol, 18(1), 2017, 70.
68. Cheng, S., Rhee, E.P., Larson, M.G., Lewis, G.D., McCabe, E.L., Shen, D., et al. Metabolite profiling identifies pathways associated with metabolic risk in humans. Circulation 125:18 (2012), 2222–2231.
69. Gu, Y., Wang, X., Li, J., Zhang, Y., Zhong, H., Liu, R., et al. Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment. Nat Commun, 8(1), 2017, 1785.